All In Biotech

Drug Trial Radar · NCT06615193

A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor

A Phase Ia/Ib, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor

Last checked: Nov 19, 2026Latest source record: Sep 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

111

Planned (sponsor's estimate)

Start

Aug 12, 2024

Primary completion

Jun 24, 2026

Study completion Feb 1, 2028

Sponsor

Sponsor type
Industry
First posted
Sep 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2005 in patients with relapsed/refractory B-cell lymphoma and advanced solid tumors.

Conditions

  • Advanced Solid Tumors
  • Refractory Lymphoma
  • Relapsed Hematologic Malignancy

Interventions

  • HDM2005Drug

    HDM2005 will be administered via IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicity (DLT) events (for dose escalation phase)Time frame: up to 21 days following first dose
  2. Incident and severity of adverse events(for dose escalation phase)Time frame: Until 28 days after the last dose or initiation of a new antineoplastic therapy, whichever occurs first
  3. Objective Response Rate (ORR)(for dose expansion phase)Time frame: Until withdrawal of consent, loss to follow-up, initiation of other new antineoplastic therapy, end of study, or study termination by the sponsor, whichever occurs first (up to approximately 3.5 years)
  4. Recommended Phase 2 Dose (RP2D) (for dose expansion phase)Time frame: Approximately 3.5 years

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • The Institute of Hematology and Blood Diseases Hospital at the Chinese Academy of Medical Sciences

    Tianjing, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Recruiting

  • The First Affiliated Hospital Of Nanchang University

    Nanchang, Jiangxi, China · Not yet recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Not yet recruiting

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.